News Related to Glucose-Dependent Insulinotropic Polypeptide Receptor

Related coverage linked through entity extraction aliases.

GLP-1 Therapies Show Antiinflammatory and Cardiovascular Benefits Beyond Metabolic Effects

Feb 15, 2026

Recent reviews highlight expanding clinical benefits of GLP-1-based therapies, including antiinflammatory actions across multiple organs and cardiovascular risk reduction, with combination approaches emerging for obesity treatment.

Taltz and Zepbound Combination Achieves Superior Results in Psoriasis and Obesity Trial

Feb 18, 2026

Phase 3b TOGETHER-PsO trial shows concomitant use of ixekizumab and tirzepatide delivered superior skin clearance and weight loss versus monotherapy in adults with moderate-to-severe plaque psoriasis and obesity or overweight.